Accuray (NSDQ:ARAY) yesterday posted second-quarter results that beat the consensus forecast on Wall Street. The Sunnyvale, Calif.-based radiation oncology company reported profits of $4.8 million, or 5¢ per share, on sales of $97.5 million for the three months ended Dec. 31, 2020, for a bottom-line slide of -55.5% sales loss of -1.4% compared with Q2 2020. […]
Accuray Inc.
Accuray ticks up on Street-beating Q1
Accuray (NSDQ:ARAY) shares ticked up today on first-quarter results that came in ahead of the consensus forecast. The Sunnyvale, Calif.-based radiotherapy device maker posted profits of $402,000, breaking even on a per-share basis, on sales of $85.3 million for the three months ended Sept. 30, 2020, for a bottom-line gain from losses of more than -$9.3 […]
Accuray dips on mixed bag Q4
Accuray (NSDQ:ARAY) shares took a hit today on fourth-quarter results that were mixed compared to the consensus forecast. The Sunnyvale, Calif.-based radiotherapy device maker posted losses of -$823,000, or -1¢ per share, on sales of $94.98 million for the three months ended June 30, 2020, for a 41.2% bottom-line gain on a sales decline of -19.1%. […]
Accuray launches CyberKnife S7 system
Accuray (NSDQ:ARAY) announced today that it launched its CyberKnife S7 system for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Using real-time artificial intelligence-driven motion tracking and synchronization, CyberKnife S7 offers treatments for SRS and SBRT in as little as 15 minutes, according to a news release. The system’s AI adapts radiation delivery to patient […]
Accuray beats The Street in Q3 results
Accuray posted third-quarter results that beat the consensus forecast on Wall Street but lowered its financial guidance for 2020. The Sunnyvale, Calif.-based company reported profits of $2.6 million, or 3¢ per share, on sales of $99.5 million for the three months ended March 31, for a bottom-line loss of -93.5% sales loss of -3.6% compared […]
Accuray beats The Street on earnings and revenue in Q2 results
Accuray (NSDQ:ARAY) posted second-quarter results that beat the consensus forecast on Wall Street. The Sunnyvale, Calif.-based company reported profits of $10.7 million, or 12¢ per share, on sales $98.8 million for three months ended Dec. 31, 2019 for a sales loss of -48.6% compared with Q2 2019. Adjusted to exclude one-time items, earnings per share were […]
Accuray shares drop as bottom line, revenues slide
Accuray (NSDQ:ARAY) shares are down today after the company reported decreased sales and profits in the first quarter of fiscal 2020. The Sunnyvale, Calif.-based radiotherapy device maker posted losses of -$9.4 million, or -11¢ per share, on sales of $89.6 million for the three months ended Sept. 30, for a bottom-line slide of -13% on a […]
Smith & Nephew taps ex-Roche chief Diggelman for CEO | Personnel Moves, October 21, 2019
Smith & Nephew (NYSE:SNN) today named former Roche (PINK:RHHBY) chief Roland Diggelmann to replace Namal Nawana next month. Nawana, named to succeed Olivier Bohuon last year, is stepping down effective Nov. 1 “to pursue other opportunities outside of the U.K.,” the London-based healthcare giant said. Nawana is slated to stay on until Dec. 31 to […]
FDA lures Vyaire exec Desai for CTO | Personnel Moves, August 23, 2019
The FDA lured former Vyaire Medical executive Vid Desai to take over as permanent CTO, according to Politico. Desai replaces acting CTO Mohammed Sohail Chaudhry, who’s held the role on an interim basis since 2015. Ebb Therapeutics puts Röösli in the corner office Insomnia device maker Ebb Therapeutics said yesterday that it put Eduard Röösli […]
Accuray slips on Q4 earnings miss
Accuray (NSDQ:ARAY) shares took a hit on lower-than-expected fiscal fourth-quarter earnings and soft guidance for fiscal 2020. The Sunnyvale, Calif.-based radiotherapy device maker posted losses of -$1.4 million, or -2¢ per share, on sales of $97.2 million for the three months ended June 30, widening its losses by 48.0% on sales growth of 0.8% compared with […]
Biomet vet Serbousek to succeed Mason as Orthofix CEO | Personnel Moves, August 13, 2019
Orthofix (NSDQ:OFIX) last week named a successor for president & CEO Brad Mason in November, tapping Jon Serbousek as president of its spine business effective August 5. Mason is slated to retire Oct. 31; Serbousek, a 30-year medtech veteran with stints at Biomet, Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ) unit DePuy Orthopaedics, is due to […]
